






# ICH1132: a Promising Alternative for Tumor Growth Inhibition Studies

New study shows that ICH1132 is an established alternative to BE0146 for tumor growth inhibition studies, showcasing significant early-stage efficacy and a consistent performance profile.


	<b>Early-Stage Efficacy</b>	Significant tumor growth inhibition observed on days 14, 17, and 19 in our recent study
	<b>Consistent Performance</b>	Trend towards higher tumor growth inhibition percentages compared to BE0146
	<b>Lower Endotoxin Levels</b>	ICH1132 (0.013 EU/mg) vs BE0146 (0.056 EU/mg), potentially beneficial for certain research contexts
	<b>Similar Safety Profile</b>	Comparable effects on body weight to BE0146, indicating similar tolerability

## ICH1132 vs BE0146: Tumor Growth Inhibition Tumor Volume Over Time



# ICH1132: a Promising Alternative for Tumor Growth Inhibition Studies

## Body Weight Change Over Time



## Key Benefits

- ✓ Potential for clearer results in early-stage tumor growth studies
- ✓ Opportunity to explore the impact of lower endotoxin levels
- ✓ Supports the 3Rs principle in animal research
- ✓ Viable alternative to BE0146

"Our comparative study has shown some interesting trends for ICH1132, particularly in the early stages of tumor growth inhibition. While the differences weren't maintained throughout the entire study period, the consistent trend towards slightly higher efficacy is noteworthy. We're interested in seeing how ICH1132 performs across different research settings and how it might contribute to more refined experimental protocols."

Dr. Elaine Zhang, Lead Researcher

